Published in Nat Biotechnol on November 01, 2000
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A (2002) 2.35
Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A (2002) 2.01
Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 1.92
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest (2002) 1.67
Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A (2007) 1.53
The neovasculature homing motif NGR: more than meets the eye. Blood (2008) 1.46
Navigare necessere est. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery. EMBO Rep (2005) 1.42
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A (2002) 1.26
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing. J Biol Chem (2012) 1.12
De novo design of a tumor-penetrating peptide. Cancer Res (2012) 1.12
Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget (2011) 1.08
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
Combinatorial ligand-directed lung targeting. Proc Am Thorac Soc (2009) 1.07
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem (2010) 1.05
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release (2010) 1.04
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer (2009) 1.03
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 1.00
Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci U S A (2012) 0.99
Issues related to targeted delivery of proteins and peptides. AAPS J (2006) 0.98
Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med (2012) 0.96
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Chromogranin A and derived peptides in health and disease. J Mol Neurosci (2012) 0.91
CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 0.91
Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol (2015) 0.89
A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy. J Biol Chem (2014) 0.88
Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther (2013) 0.88
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 0.88
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget (2012) 0.88
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs (2013) 0.88
Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw (2012) 0.87
Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin Drug Discov (2007) 0.87
Therapeutic Enzyme-Responsive Nanoparticles for Targeted Delivery and Accumulation in Tumors. Adv Mater (2015) 0.86
Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infect Immun (2005) 0.86
Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging (2011) 0.85
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol (2010) 0.84
Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology (2012) 0.84
Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues. J Histochem Cytochem (2011) 0.84
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer (2012) 0.82
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo. Bioconjug Chem (2011) 0.81
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. Br J Cancer (2012) 0.79
Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights (2008) 0.79
Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment. Oncotarget (2014) 0.78
Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif. Chem Biol Drug Des (2010) 0.78
Identification of tissue-specific targeting peptide. J Comput Aided Mol Des (2012) 0.78
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol (2010) 0.78
Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A (2016) 0.77
Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth. PLoS One (2012) 0.77
NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells. Br J Cancer (2013) 0.77
Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth. J Transl Med (2016) 0.76
NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. Nano Res (2016) 0.76
Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorg Med Chem Lett (2010) 0.75
Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain. Int J Mol Sci (2017) 0.75
Synthesis of tumor necrosis factor α for use as a mirror-image phage display target. Org Biomol Chem (2016) 0.75
Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38. PLoS One (2015) 0.75
Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine. J Biomed Sci (2016) 0.75
Improving drug uptake and penetration into tumors: current and forthcoming opportunities. Front Oncol (2013) 0.75
The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms. Oncoimmunology (2015) 0.75
Recombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitro. Cytotechnology (2014) 0.75
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Transl Oncol (2017) 0.75
Artificial neural network study on organ-targeting peptides. J Comput Aided Mol Des (2009) 0.75
NGR-peptide-drug conjugates with dual targeting properties. PLoS One (2017) 0.75
Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. Adv Funct Mater (2017) 0.75
Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cells. Chem Sci (2017) 0.75
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF. Clin Exp Metastasis (2015) 0.75
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation (1995) 2.91
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A (1985) 2.72
Depolarization of central terminals of Group I afferent fibres from muscle. J Physiol (1962) 2.51
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J (1999) 2.12
Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother (1984) 2.01
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J (2002) 1.98
Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2013) 1.76
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res (1988) 1.70
NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem (2000) 1.64
Mutant p53: an oncogenic transcription factor. Oncogene (2007) 1.62
Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol (2000) 1.60
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res (1997) 1.58
The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci (2007) 1.51
Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 1.43
An international comparison of knowledge levels of medical students: the Maastricht Progress Test. Med Educ (1996) 1.42
Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J Biol Chem (2000) 1.40
Ethnic differences in red blood cell sodium/lithium countertransport and metabolic correlates of hypertension: an international collaborative study. Am J Hypertens (1998) 1.39
Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene (1999) 1.35
Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. Mol Cell Biol (1996) 1.33
Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle. Mol Cell Biol (2001) 1.32
The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol (2001) 1.29
Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. Cancer Res (1986) 1.29
p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood (1998) 1.28
Paradoxical enhancement of S-adenosylmethionine decarboxylase in rat tissues following administration of the specific inhibitor methyl glyoxal bis(guanylhydrazone). Biochem Biophys Res Commun (1973) 1.27
Structure and growth-dependent regulation of the human cyclin B1 promoter. Exp Cell Res (1995) 1.26
p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol (2000) 1.25
Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation. Cell Growth Differ (1996) 1.23
Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ (2006) 1.21
Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res (2000) 1.20
Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue. Cancer Res (1988) 1.20
Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 1.15
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol (1997) 1.15
Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.14
Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin. J Hosp Infect (1986) 1.13
Functional and immunological analysis of recombinant mouse H- and L-ferritins from Escherichia coli. Protein Expr Purif (2000) 1.13
Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Exp Cell Res (1994) 1.11
Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care (2001) 1.10
Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc Natl Acad Sci U S A (1984) 1.10
Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int (1998) 1.09
Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem (2000) 1.08
The cyclin B1 gene is actively transcribed during mitosis in HeLa cells. EMBO Rep (2001) 1.06
Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol (2001) 1.06
Biomass production and studies on Rhodopseudomonas palustris grown in an outdoor, temperature controlled, underwater tubular photobioreactor. J Biotechnol (2001) 1.06
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene (2009) 1.05
Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood (1994) 1.05
The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med (1997) 1.05
p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene (1997) 1.05
Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem (1999) 1.04
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. J Med Chem (2000) 1.03
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 1.00
HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif (2009) 0.99
HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ (2007) 0.99
On the development of specific inhibitors of animal polyamine biosynthetic enzymes. Ital J Biochem (1976) 0.98
SPEAR indicates pesticide effects in streams--comparative use of species- and family-level biomonitoring data. Environ Pollut (2009) 0.98
HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene (2011) 0.97
The gene for SP-40,40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics (1991) 0.97
Septal deviation in newborn infants. Int J Pediatr Otorhinolaryngol (1986) 0.96
The association of the Nm23-M1 protein and beta-tubulin correlates with cell differentiation. Exp Cell Res (1995) 0.96
Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ (2005) 0.96
E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells. Oncogene (1999) 0.95
Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology (1995) 0.95
Human macrophage gamma interferon decreases gene expression but not replication of Mycobacterium tuberculosis: analysis of the host-pathogen reciprocal influence on transcription in a comparison of strains H37Rv and CMT97. Infect Immun (2001) 0.95
Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene (1995) 0.95
Integrin (alpha 6/beta 4) expression in human lung cancer as monitored by specific monoclonal antibodies. Cancer Res (1990) 0.95
Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation? Transplant Proc (1997) 0.94
Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene (2009) 0.94
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest (1996) 0.94
Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol (1996) 0.94
S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene (2006) 0.94
Orphan receptor hepatocyte nuclear factor-4 antagonizes estrogen receptor alpha-mediated induction of human coagulation factor XII gene. Endocrinology (1998) 0.94
The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. Oncogene (1999) 0.93
Inhibition of ERalpha-mediated trans-activation of human coagulation factor XII gene by heteromeric transcription factor NF-Y. Endocrinology (2001) 0.93
Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol (1997) 0.93
Biochemical characterization and crystal structure of a recombinant hen avidin and its acidic mutant expressed in Escherichia coli. Eur J Biochem (1998) 0.92
Haplotype variation in a mitochondrial tandem repeat of Norway spruce (Picea abies) populations suggests a serious founder effect during postglacial re-colonization of the western Alps. Mol Ecol (2001) 0.92
p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ (2004) 0.92
Biodegradation of dibenzothiophene by a nodulating isolate of Rhizobium meliloti. Can J Microbiol (1998) 0.91
Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem (2000) 0.91
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res (2001) 0.91
Insulin-induced phosphorylation of the beta-4 integrin subunit expressed on murine metastatic carcinoma cells. Mol Carcinog (1989) 0.91
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res (1997) 0.90
Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem (2000) 0.90
Integrin Beta-4 expression in colorectal-cancer. Int J Oncol (1994) 0.90
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther (1999) 0.90
The afferent and preganglionic parasympathetic innervation of the rat liver, demonstrated by the retrograde transport of horseradish peroxidase. J Auton Nerv Syst (1983) 0.90
Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Eur J Biochem (1996) 0.90
Urinary exosomes and diabetic nephropathy: a proteomic approach. Mol Biosyst (2013) 0.90
Aspirin inhibits platelet 12-hydroxy-eicosatetraenoic acid formation. J Lab Clin Med (1986) 0.89
Suramin induces deoligomerization of human tumor necrosis factor alpha. J Biol Chem (1993) 0.89
Coordinate changes of polyamine metabolism regulatory proteins during the cell cycle of normal human dermal fibroblasts. FEBS Lett (1999) 0.89
The decarboxylation of S-adenosylmethionine by detergent-treated extracts of rat liver. Biochem J (1979) 0.89